Whether you are just beginning to explore your options or ready to optimize a protocol you have already started, the depth of information available through the platform can make the difference between a good outcome and a great one
Fats That Slow Everything Down (In a Good Way) Fat has had a rough PR cycle since basically the early 2000s
Nat Med 28(3):591598
Disclosures: Kamalpreet Hara: Nothing to Disclose, Alberto Calleri: Nothing to Disclose, Tiffany Wu: Nothing to Disclose, Vijay Shah: Boehringer Ingelheim: Consultant, GSK: Consultant, GENFIT SA: Consultant, Intercept Pharmaceuticals, Inc.: Advisor, Korro Bio, Inc.: Consultant, Mallinckrodt Pharmaceuticals: Advisor, Novo Nordisk A/S: Consultant, Resolution Therapeutics, Ltd.: Advisor, Seal Rock Therapeutics, Ltd.: Consultant, Surrozen: Advisor, Patrick Kamath: Sequana: Advisor, NovoNordisk: Advisor, Douglas Simonetto: Nothing to Disclose, Nothing to Disclose, Nothing to Disclose, Nothing to Disclose 1590 A PROSPECTIVE STUDY EVALUATING THE PREVALENCE OF STEATOTIC LIVER DISEASE AND ADVANCED FIBROSIS AND CIRRHOSIS IN OVERWEIGHT AND OBESE INDIVIDUALS IN THE UNITED STATES Alexander Yang 1 Monica Tincopa 1 Federica Tavaglione 2 Veeral Ajmera 1 Lisa Richards 1 Maral Amangurbanova 1 Christian Butcher 1 Christie Hernandez 1 Egbert Madamba 1 Seema Singh 1 Ricki Bettencourt 1 Bernd Schnabl 1 Claude Sirlin 1 Rohit Loomba 1 , 1 University of California, San Diego, 2 University Campus Bio-Medico of Rome Background: In 2023, new steatotic liver disease (SLD) nomenclature was introduced to include metabolic dysfunction-associated liver disease (MASLD), alcohol-associated liver disease (ALD), and the entity metabolic dysfunction and alcohol-associated liver disease (MetALD) accounting for those with both metabolic risk factors and significant alcohol use
Also, hyperglycemia causes increased glucose and sodium reabsorption at the proximal tubule reducing the sodium delivery to the macula densa
